Age and Sex Effects on the Single- and Multiple-Dose Safety and Pharmacokinetics of the New Renin Inhibitor ACT-178882DINGEMANSE, Jasper; NICOLAS, Laurent.Cardiovascular therapeutics (Print). 2013, Vol 31, Num 5, pp 307-313, issn 1755-5914, 7 p.Article

Integrated pharmacokinetics and pharmacodynamics in drug developmentDINGEMANSE, Jasper; APPEL-DINGEMANSE, Silke.Clinical pharmacokinetics. 2007, Vol 46, Num 9, pp 713-737, issn 0312-5963, 25 p.Article

Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatinHOCH, Matthias; HOEVER, Petra; THEODOR, Rudolf et al.European journal of clinical pharmacology. 2013, Vol 69, Num 6, pp 1235-1245, issn 0031-6970, 11 p.Article

Influence of different degrees of liver impairment on the pharmacokinetics of clazosentanBRUDERER, Shirin; DETISHIN, Victor; TSVITBAUM, Nahum et al.British journal of clinical pharmacology. 2011, Vol 71, Num 1, pp 52-60, issn 0306-5251, 9 p.Article

Lack of Renal Improvement with Nonselective Endothelin Antagonism with Tezosentan in Type 2 Hepatorenal SyndromeWONG, Florence; MOORE, Kevin; DINGEMANSE, Jasper et al.Hepatology (Baltimore, Md.). 2008, Vol 47, Num 1, pp 160-168, issn 0270-9139, 9 p.Article

Phospholipidosis in healthy subjects participating in clinical studies: Ultrastructural findings in white blood cellsPOSPISCHIL, Andreas; WALTHER, Paul; DINGEMANSE, Jasper et al.Experimental and toxicologic pathology (Print). 2010, Vol 62, Num 5, pp 567-571, issn 0940-2993, 5 p.Article

Multiple-dose pharmacokinetics of intranasally administered IS-159 in healthy subjectsVAN GIERSBERGEN, Paul L. M; DINGEMANSE, Jasper.European journal of drug metabolism and pharmacokinetics. 2003, Vol 28, Num 1, pp 49-54, issn 0378-7966, 6 p.Article

Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882DINGEMANSE, Jasper; NICOLAS, Laurent B; VAN BORTEL, Luc et al.European journal of clinical pharmacology. 2014, Vol 70, Num 6, pp 675-684, issn 0031-6970, 10 p.Article

Investigation of a correlation between monoamine oxidase B and catechol-O-methyltransferase activity in human blood cellsDINGEMANSE, Jasper; ZÜRCHER, Gerhard; KETTLER, Rolf et al.European journal of pharmaceutical sciences. 2000, Vol 12, Num 2, pp 159-163, issn 0928-0987Article

Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolamDINGEMANSE, Jasper; NICOLAS, Laurent; BINKERT, Christoph et al.Fundamental & clinical pharmacology. 2013, Vol 27, Num 6, pp 698-710, issn 0767-3981, 13 p.Article

Mutual pharmacokinetic interactions between steady-state bosentan and sildenafilBURGESS, Gary; HOOGKAMER, Hans; COLLINGS, Lorraine et al.European journal of clinical pharmacology. 2008, Vol 64, Num 1, pp 43-50, issn 0031-6970, 8 p.Article

Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonistVAN GIERSBERGEN, Paul L. M; DINGEMANSE, Jasper.European journal of clinical pharmacology. 2007, Vol 63, Num 2, pp 151-158, issn 0031-6970, 8 p.Article

Clinical pharmacology of bosentan, a dual endothelin receptor antagonistDINGEMANSE, Jasper; VAN GIERSBERGEN, Paul L. M.Clinical pharmacokinetics. 2004, Vol 43, Num 15, pp 1089-1115, issn 0312-5963, 27 p.Article

Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bileDINGEMANSE, Jasper; VAN GIERSBERGEN, Paul L. M.British journal of clinical pharmacology. 2004, Vol 57, Num 3, pp 344-348, issn 0306-5251, 5 p.Article

Comparative Pharmacokinetic, Pharmacodynamic, Safety, and Tolerability Profiles of 3 Different Formulations of Epoprostenol Sodium for Injection in Healthy MenNICOLAS, Laurent B; GUTIERREZ, Marcelo M; DINGEMANSE, Jasper et al.Clinical therapeutics. 2013, Vol 35, Num 4, pp 440-449, issn 0149-2918, 10 p.Article

Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjectsSIDHARTA, Patricia N; DIAMANT, Zuzana; DINGEMANSE, Jasper et al.Fundamental & clinical pharmacology. 2014, Vol 28, Num 6, pp 690-699, issn 0767-3981, 10 p.Article

Validated LC―MS/MS method for the quantitative determination of the glucosylceramide synthase inhibitor miglustat in mouse plasma and human plasma and its application to a pharmacokinetic studySPIEKER, Elke; WAGNER-REDEKER, Winfried; DINGEMANSE, Jasper et al.Journal of pharmaceutical and biomedical analysis. 2012, Vol 59, pp 123-129, issn 0731-7085, 7 p.Article

Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhageZISOWSKY, Jochen; FUSEAU, Eliane; BRUDERER, Shirin et al.European journal of clinical pharmacology. 2014, Vol 70, Num 4, pp 409-419, issn 0031-6970, 11 p.Article

Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjectsHOCH, Matthias; HOEVER, Petra; ALESSI, Federica et al.European journal of clinical pharmacology. 2013, Vol 69, Num 3, pp 523-532, issn 0031-6970, 10 p.Article

Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between Caucasian and Japanese subjectsDINGEMANSE, Jasper; GUNAWARDENA, Kulasiri A; VAN GIERSBERGEN, Paul L. M et al.British journal of clinical pharmacology. 2006, Vol 61, Num 4, pp 405-413, issn 0306-5251, 9 p.Article

Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjectsDINGEMANSE, Jasper; BURY, Michele; HUSSAIN, Yasmin et al.Drug metabolism and disposition. 2000, Vol 28, Num 12, pp 1411-1416, issn 0090-9556Article

Pharmacokinetics, Pharmacodynamics, and Tolerability of ACT-077825, a New Direct Renin Inhibitor After Multiple-ascending Doses in Healthy SubjectsNICOLAS, Laurent B; GUTIERREZ, Marcelo; BINKERT, Christoph et al.Journal of cardiovascular pharmacology. 2013, Vol 61, Num 1, pp 42-50, issn 0160-2446, 9 p.Article

Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjectsNICOLAS, Laurent B; KRAUSE, Andreas; GUTIERREZ, Marcelo M et al.British journal of clinical pharmacology. 2012, Vol 74, Num 6, pp 978-989, issn 0306-5251, 12 p.Article

Determination of tezosentan, a parenteral endothelin receptor antagonist, in human plasma by liquid chromatography-tandem mass spectrometryVAN GIERSBERGEN, Paul L. M; WIPFLI, Peter; DINGEMANSE, Jasper et al.Journal of chromatography. B. 2003, Vol 792, Num 2, pp 369-373, issn 1570-0232, 5 p.Article

Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjectsDINGEMANSE, Jasper; CLOZEL, Martine; VAN GIERSBERGEN, Paul L. M et al.British journal of clinical pharmacology. 2002, Vol 53, Num 4, pp 355-362, issn 0306-5251, 8 p.Article